Table 4 In-ICU characteristics and outcomes of the 69 ECMO-treated SRD flare patients: hospital survivors vs. nonsurvivors
From: Outcomes of severe systemic rheumatic disease patients requiring extracorporeal membrane oxygenation
Characteristic | n/n* | Survivors n = 31 | Nonsurvivors n = 38 | P value |
|---|---|---|---|---|
Women | 16 (51.6) | 27 (71.1) | 0.1 | |
Age at admission, years | 37.6 ± 16.2 | 44.5 ± 14.6 | 0.07 | |
Symptom-onset-to-ICU interval, days | 8 [3–23] | 18 [7–42] | 0.02 | |
Hospital-to-ICU interval, days | 3 [1–8] | 9 [4–22.2] | 0.002 | |
Days in ICU | 19 [9–77] | 17 [5–36] | 0.1 | |
Pre-admission SRD | ||||
Connective tissue diseases | 15 (48.4) | 34 (89.5) | 0.2 | |
Vasculitides | 6 (19.4) | 3 (7.9) | 0.2 | |
Corticosteroids | 10 (32.3) | 19 (50) | 0.1 | |
Immunosuppressant(s) | 7 (22.6) | 13 (34.2) | 0.3 | |
Heart involvement | 6 (19.4) | 16 (42.1) | 0.04 | |
In-ICU SRD | ||||
In-ICU diagnosis | 12 (38.7) | 17 (44.7) | 0.6 | |
Corticosteroids | 24 (77.4) | 29 (76.3) | 0.9 | |
Immunosuppressant(s) | 12 (38.7) | 18 (47.4) | 0.5 | |
Organ failures at ICU admission | ||||
Day-0 SAPS II | 55 [30–66] | 62 [48–73] | 0.06 | |
Day-0 SOFA score | 12 [8–14] | 15 [12–18] | 0.006 | |
ECMO | ||||
VV-ECMO | 14 (45.2) | 17 (44.7) | 0.9 | |
RESP score | 1.5 [− 0.2 to 3] | − 2 [− 4 to 0] | 0.007 | |
VA-ECMO | 17 (54.8) | 21 (55.3) | 0.9 | |
SAVE score | 0 [− 6 to 1] | − 8.5 [− 13.7 to − 3.5] | 0.001 | |
Days on ECMO | 48 [7–73] | 11 [4–29] | 0.2 | |
ECMO complications | ||||
Limb ischemia | 3 (9.7) | 3 (7.9) | 0.8 | |
Insertion-site hemorrhage | 5 (16.1) | 10 (26.3) | 0.1 | |
Cannula-related infection | 8 (25.8) | 7 (18.4) | 0.5 | |
In-ICU organ support | ||||
Dobutamine | 18 (58.1) | 16 (42.1) | 0.2 | |
Vasopressors | 25 (80.6) | 37 (97.4) | 0.02 | |
Mechanical ventilation | 29 (93.5) | 37 (97.4) | 0.4 | |
Renal replacement therapy | 11 (35.5) | 24 (63.2) | 0.02 | |
Highest in-ICU value | ||||
Arterial lactate, mmol/L | 5.5 [3.1–8.8] | 13.1 [5.4–18.2] | 0.004 | |
Troponin, ULN | 28/37 | 15.6 [5.3–84.4] | 10.3 [0.7–37.9] | 0.1 |
Serum creatinine, µmol/L | 30/34 | 118 [89–342] | 149 [93–217] | 0.7 |
Lowest in-ICU value | ||||
Platelet count, G/L | 56 [30–103] | 25 [9–38] | < 0.0001 | |
Prothrombin time, % | 43 [35–60] | 34 [16–55] | 0.03 | |
Outcome | ||||
In-ICU–acquired infection | 19 (61.3) | 28 (73.7) | 0.2 | |
Fungal infection | 3 (9.7) | 9 (23.7) | 0.1 | |
Transplantation | 7 (22.6) | 1 (2.6) | 0.01 | |
Heart | 2 (6.5) | 1 (2.6) | n/a | |
Heart–kidney combined | 1 (3.2) | 0 (0) | n/a | |
Lung | 4 (12.9) | 0 (0) | n/a | |
Left ventricular assist device | 1 (3.2) | 1 (2.6) | 0.9 | |
Weaning | 23 (74.2) | 6 (15.8) | < 0.0001 | |
In-ICU mortality | 0 (0) | 37 (97.4) | < 0.0001 | |